Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

Summary

To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457

Timeline

Start

2014-08-07

Primary completion

2015-11-12

Completion

2015-11-12

Outcome

Outcome not reported

Stopped: “Novartis decided to terminate the study considering safety and tolerability concerns and limited clinical activity with CLR457 study drug administered once daily (qd).”

Drugs

Indications